Tresiba Solid As Novo Nordisk Plots Japan Growth
This article was originally published in PharmAsia News
Novo Nordisk has had its best year ever in sales terms in Japan, where its subsidiary is benefiting mainly from the strong performance of basal insulin preparation Tresiba.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.